Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Ideas for Profit: Ashok Leyland rides on multiple opportunities, accumulate for the long term

15h moneycontrol
Ashok Leyland (AL), India’s second largest commercial vehicle (CV) manufacturer, started FY19 with a strong set of numbers for the first quarter on robust volume growth and cost management. We see numerous opportunities for the company such as more organised players in the economy, strong exports, robust industry prospects, its defence strategy and focus on electric vehicles (EVs).
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland Limited - Shareholders meeting

16h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland: Riding on multiple challenges

16h moneycontrol
Ashok Leyland (AL), India’s second largest commercial vehicle (CV) manufacturer, started FY19 with a strong set of numbers for the first quarter on robust volume growth and cost management. We see numerous opportunities for the company such as more organised players in the economy, strong exports, robust industry prospects, its defence strategy and focus on electric vehicles (EVs).
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland plunges nearly 5%; brokerages cut target price up to Rs 99

19h moneycontrol
Shares of Ashok Leyland slipped nearly 5 percent intraday Thursday as brokerages cut their target price of the company.
DB 500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland aims to match industry growth in current fiscal

2018-07-18 moneycontrol
Buoyed by its quarterly performace for the period ending June 30, 2018, heavy commercial vehicle maker Ashok Leyland is aiming to match the industry's growth during the current fiscal.
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland shares slump 14%

2018-07-18 thehindubusinessline
Shares of Ashok Leyland today slumped 14 per cent after the government brought in new axle norms for load carrying capacity which experts said could hurt demand for commercial vehicles.
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland slips 14% as Macquarie maintains underperform

2018-07-18 moneycontrol
Shares of Ashok Leyland slipped nearly 14 percent to close at Rs 110.60 Wednesday as research house Macquarie maintained underperform rating on the stock with a target price of Rs 113 post June quarter numbers declared by the company on Tuesday.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG 500477 MS MS.PRA AKLS AKLD ASHOKLEY

0
Ashok Leyland slips 7% as Macquarie maintains underperform, target Rs 113

2018-07-18 moneycontrol
Shares of Ashok Leyland slipped more than 7 percent intraday Wednesday as research house Macquarie maintained underperform rating on the stock with a target price of Rs 113 post June quarter numbers declared by the company on Tuesday.
500477 AKLS AKLD ASHOKLEY

0
Ashok Leyland Limited - Shareholders meeting

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500477 AKLS AKLD ASHOKLEY

0
An evening walk down Dalal Street | Sensex up almost 200 pts, Nifty back at 11,000

2018-07-17 moneycontrol
After starting the week on a negative note, the market on Tuesday looked to reclaim its positive momentum from last week, backed by sharp gains in midcaps. The Sensex managed to end the day almost 200 points higher, while the Nifty managed to end above 11,000-mark.
IOC 500469 532617 TCHQY HINDUNILVR FEDA 532755 532187 532461 FEDS 500696 500477 FEDERALBNK ASHOKLEY SBAZ INDIGO INDUSINDBK JETAIRWAYS FDBAY 530965 AKLD TECHM 539448 PNJZY PNB AKLS

4
Eicher Motors to make low cost AC buses, open plants outside India

2018-07-17 moneycontrol
VE Commercial Vehicles (VECV), the joint venture company of Sweden’s Volvo and Delhi-based Eicher Motors, is working on a series of projects including development of low-cost AC buses, electric mobility solutions and setting up of assembly plants outside India.
505200 ECQRY 500477 500570 AKLS TATAMOTORS EICHERMOT AKLD TTM ASHOKLEY

0
Ashok Leyland Q1 profit jumps over 3-fold to Rs 370.1 crore

2018-07-17 livemint
New Delhi: Hinduja flagship firm Ashok Leyland on Tuesday reported over three-fold jump in standalone net profit at Rs370.1 crore in the first quarter ended on 30 June, riding on robust sales.
500477 AKLS AKLD ASHOKLEY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...